<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523285</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3728-I-01</org_study_id>
    <nct_id>NCT04523285</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, and Pharmacokinetics of TQB3728 Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open-label, phase I study to evaluate tolerance and pharmacokinetics of TQB3728&#xD;
      tablets in subjects with advanced solid tumor or hematologic tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>30minutes pre-dose on day 1and day 8;1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 24hour, 72hour post-dose on day 1 and day 8; 48hour, 96hour post-dose on day 1.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3728 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>30minutes pre-dose on day 1and day 8;1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 24hour, 72hour post-dose on day 1 and day 8; 48hour, 96hour post-dose on day 1.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQB3738 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>30minutes pre-dose on day 1and day 8; 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 24hour, 72hour post-dose on day 1 and day 8; 48hour, 96hour post-dose on day 1.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3728 by assessment of area under the plasma concentration time curve from zero to specific time or infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Solid Tumor or Hematologic Tumor</condition>
  <arm_group>
    <arm_group_label>TQB3728 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3728 tablets administered orally, once a week in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3728</intervention_name>
    <description>TQB3728 tablets is a small molecule oral drug.</description>
    <arm_group_label>TQB3728 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Understood and signed an informed consent form. 2.Histologically or cytologically&#xD;
             confirmed advanced/metastatic or refractory solid tumor or lymphoma. No approved&#xD;
             standard treatment regimen or ineffective or intolerant to standard treatment regimen.&#xD;
&#xD;
             3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life&#xD;
             expectancy ≥12 weeks.&#xD;
&#xD;
             4. Has at least one measurable lesion (solid tumors based on RECIST V1.1, lymphoma&#xD;
             based on Lugano 2014).&#xD;
&#xD;
             5.Adequate organ system function. 6.Male or female subjects should agree to use an&#xD;
             adequate method of contraception starting with the first dose of study therapy through&#xD;
             6 months after the last dose of study (such as intrauterine devices , contraceptives&#xD;
             or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are&#xD;
             received within 7 days before the first administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Hypersensitivity to TQB3728 or its excipient. 2.Has received chemotherapy,&#xD;
             radiotherapy, hormone therapy, immunotherapy, targeted therapy, biotherapy or any&#xD;
             other antitumor therapy within 4 weeks before first administration.&#xD;
&#xD;
             3.Has received allogeneic hematopoietic stem cell transplantation or organ&#xD;
             transplantation, or received autologous hematopoietic stem cell transplantation within&#xD;
             12 weeks before administration.&#xD;
&#xD;
             4.Has multiple factors affecting oral medication. 5.Has primary CNS lymphoma or CNS&#xD;
             metastasis with untreated or uncontrolled symptoms.&#xD;
&#xD;
             6.Pregnant or lactating women. 7.Has severe or uncontrolled systemic disease. 8.Has&#xD;
             serious cardiovascular diseases. 9.Has neurological or mental disorders. 10.Has&#xD;
             autoimmune disease or diseases requiring systemic hormones or immunosuppressive drugs.&#xD;
&#xD;
             11.Has active viral infection. 12.The related toxicity of previous anti-tumor therapy&#xD;
             has not recovered to CTCAE ≤ grade 1, except for hair loss.&#xD;
&#xD;
             13. Has received major surgery within 4 weeks before the first administration. 14.Has&#xD;
             participated in other clinical trials within 4 weeks before participating in this&#xD;
             trial.&#xD;
&#xD;
             15.According to the judgement of the researchers, there are other factors that&#xD;
             subjects are not suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shusen Wang, Doctor</last_name>
    <phone>020-87342693</phone>
    <email>wangshs@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Wang, Doctor</last_name>
      <phone>020-87342693</phone>
      <email>wangshs@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Shusen Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

